<p>Eli Lilly e AtaiBeckley, azienda biofarmaceutica in fase clinica quotata al Nasdaq che sviluppa terapie innovative per le patologie mentali, hanno raggiunto un accordo per l'acquisizione della...

The latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally be embracing a long-dismissed field of research.

AtaiBeckley shares jumped 64.70% after hours following reports that Eli Lilly is in talks to acquire the psychedelic drugmaker at a premium.

Eli Lilly is reportedly negotiating to acquire psychedelic drugmaker AtaiBeckley. AtaiBeckley shares experienced a significant surge following the news of these discussions. The…